Related Experiment Video
Updated: Jan 12, 2026
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
lncRNA IGFL2-AS1 mediates NSCLC chemoresistance via YBX1-induced HSPA1A/RAP1 activation
Hongliang Dong1,2,3, Yunxiu Xia2,4, Jingjing Qi5
1Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, 661 Huanghe Second Road, 256600, Binzhou, People's Republic of China.
Background:
The development of drug resistance in cancer is associated with multiple malignant properties, including proliferative progression, metastasis, and stemness. Long noncoding RNAs (lncRNAs) reportedly contribute to multidrug resistance in lung cancer. However, functional and mechanistic studies of key lncRNAs associated with lung cancer are lacking.
Methods:
Candidate lncRNA IGFL2-AS1 and its downstream target, the HSPA1A and RAP1 cascade, were identified using RNA sequencing. In vitro functional assays, including proliferation, clonal formation, Transwell migration, sphere formation, and drug sensitivity test, were conducted to explore the function of the IGFL2-AS1/HSPA1A axis in lung cancer. For in vivo functional validation, subcutaneous implantation and tail vein injection of luciferase-tagged lung cancer cells were performed in mouse models. Moreover, RNA pulldown, RNA immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP), and point/truncated mutations were utilized to dissect the mechanisms underlying the activation of the YBX1-mediated IGFL2-AS1/HSPA1A axis. Pharmacological inhibition of HSPA1A was performed to restore chemotherapy sensitivity and attenuate lung cancer cell metastasis in vivo. Finally, tissue microarray staining was employed to evaluate the expression of the YBX1/IGFL2-AS1/HSPA1A/RAP1 axis in lung cancer specimens and its correlation with prognosis.
Results:
IGFL2-AS1, stimulated by C/EBPβ, was aberrantly upregulated in chemoresistant cell lines and lung cancer specimens. IGFL2-AS1 promoted lung cancer proliferation, metastasis, drug resistance, and stemness by upregulating HSPA1A expression both in vitro and in vivo. Mechanistically, IGFL2-AS1 recruited YBX1 to the HSPA1A promoter, facilitating its transcription. Pharmacological inhibition of HSPA1A restored the sensitization of A549 cells resistant to cisplatin and 5-fluorouracil via the downstream RAP1 signaling cascade. Notably, the YBX1/IGFL2-AS1/HSPA1A axis was consistently activated in lung cancer specimens and correlated with poor patient prognosis.
Conclusions:
This study demonstrated that the YBX1-modulated IGFL2-AS1/HSPA1A/RAP1 axis is aberrantly activated in lung cancer cells and is associated with unfavorable prognosis, highlighting its potential as a novel therapeutic target in clinical settings.
Insights
This study reveals that the IGFL2-AS1 long noncoding RNA promotes lung cancer progression and drug resistance by activating the HSPA1A/RAP1 pathway. Targeting this axis offers a potential new therapeutic strategy for lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Drug resistance in cancer is linked to increased malignancy, including metastasis and stemness.
- Long noncoding RNAs (lncRNAs) are implicated in multidrug resistance in lung cancer, but key lncRNAs require further study.
Purpose of the Study:
- To investigate the role of lncRNA IGFL2-AS1 in lung cancer progression and drug resistance.
- To elucidate the functional and mechanistic interplay of the IGFL2-AS1/HSPA1A/RAP1 axis in lung cancer.
Main Methods:
- RNA sequencing identified IGFL2-AS1 and its downstream targets.
- In vitro and in vivo assays assessed IGFL2-AS1 function in proliferation, metastasis, and drug sensitivity.
- Molecular techniques (RNA pulldown, RIP, ChIP) dissected the YBX1-mediated activation mechanism.
- Pharmacological inhibition of HSPA1A and tissue microarray analysis were performed.
Main Results:
- IGFL2-AS1 was upregulated in chemoresistant lung cancer and promoted proliferation, metastasis, drug resistance, and stemness.
- IGFL2-AS1 upregulates HSPA1A via YBX1 recruitment to the promoter, activating the RAP1 pathway.
- HSPA1A inhibition restored chemosensitivity and reduced metastasis.
- The YBX1/IGFL2-AS1/HSPA1A/RAP1 axis correlated with poor prognosis in lung cancer patients.
Conclusions:
- The YBX1-modulated IGFL2-AS1/HSPA1A/RAP1 axis is activated in lung cancer.
- This axis is associated with unfavorable patient prognosis.
- The axis represents a potential novel therapeutic target for lung cancer.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...